CoChat
Sign Up
Cited by 95Lymphoma Diagnosis and TreatmentRadiopharmaceutical Chemistry and ApplicationsChronic Lymphocytic Leukemia Research

Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkin's Lymphoma Who Had Previously Responded to I-131 Tositumomab

Kaminski, Mark S., Radford, John A., Gregory, Stephanie A., Leonard, John P., Knox, Susan J., Kroll, Stewart, Wahl, Richard L.·2005·Journal of Clinical Oncology
DOI 10.1200/jco.2005.01.0892
Open this paper in CoChat — free account

Abstract

Purpose: To study efficacy and safety of re-treatment with I-131 tositumomab in patients with low-grade, follicular, or transformed low-grade B-cell lymphoma who relapsed following a response to I-131 tositumomab. Patients and Methods: A prior response ≥ 3 months to I-131 tositumomab was required. The single therapeutic dose following a dosimetric dose was adjusted to give the same total body dose (in Gy) as that used for the original dose, or was attenuated if the platelet count was less than 150,000 per mm 3 or if the prior treatment resulted in grade 4 cytopenias lasting longer than 7 days. Results: Of 32 patients enrolled, 28 completed the therapeutic dose. A median of four therapies were given before re-treatment. Eighteen (56%) of 32 patients had a complete or partial response (median duration, 15.2 months); eight (25%) had a complete response (median duration, 35 months). Five continue in response from 1.8 to 5.7 years, with a median follow-up of 35 months. The overall median response duration was not significantly different for the two treatments, with no clinical factors predicting response or its duration. Ten of 18 re-responders had longer responses with re-treatment, with five having responses ≥ 1.5 years longer. Grade 3/4 neutropenia and thrombocytopenia occurred in 50% and 43% of patients, respectively, similar to initial treatment. Antimouse antibodies developed in 10% of patients, and 12% developed elevated serum thyroid-stimulating hormone. Six patients were diagnosed with second malignancies, including four patients who developed myelodysplastic syndrome (one who had not received the therapeutic dose) and one with acute myelogenous leukemia. Conclusion: Re-treatment with I-131 tositumomab following a previous response can produce second responses that can be durable.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.01.0892

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • 131I-tositumomab therapy was successfully repeated at a 75 cGy total body dose level at months to years after initial treatment, with no evidence of additive toxicity.

    “As an example, 131 I-tositumomab therapy was successfully repeated at a 75 cGy total body dose level at months to years after initial treatment, with no evidence of additive toxicity ( 48 ).”

    From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [48]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Kaminski, M. S., Radford, J. A., Gregory, S. A., Leonard, J. P., Knox, S. J., Kroll, S., & Wahl, R. L.
Affiliations
Johns Hopkins University (US)
ORCID
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2005-11-01
Volume
23
Issue
31
Pages
7985-7993
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2005.01.0892
OpenAlex
W2152526200
Cited by
95
References
18
Citations by year
2025: 1 · 2024: 2 · 2023: 1 · 2022: 4 · 2021: 3 · 2018: 2 · 2017: 2 · 2016: 4 · 2015: 2 · 2014: 3 · 2013: 2 · 2012: 7
FWCI
8.47
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
Keywords
retreatment, non-Hodgkin lymphoma, follicular lymphoma, low-grade B-cell lymphoma, relapsed lymphoma, monoclonal antibody therapy, neutropenia, thrombocytopenia, anti-mouse antibodies, myelodysplastic syndrome, secondary malignancies
MeSH terms
Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Iodine Radioisotopes, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Male, Middle Aged, Neoplasm Recurrence, Local, Survival Rate, Lymphoma, B-Cell, Radioimmunotherapy, Treatment Outcome, Immunoconjugates, Antigens, CD20, Retreatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review